CB Insights
Technology Market Intelligence
Technology Market Intelligence
Public list: Pharma Startups (6570)
BioMarin (NASDAQ: BMRN) develops and commercializes biopharmaceuticals for serious diseases and medical conditions, focusing on product candidates that address currently unmet medical needs; suggest a clear-cut development profile; and provide an opp...Show all
Company (Alive / Active)
Phone: 415-506-6700
770 Lindaro St.
San Rafael, 94901
California, United States
| Total Funding | Date of Last Funding | |
|---|---|---|
| BioMarin Pharmaceutical | $66M | May 7, 2001 |
| See all 16 competitors | ||
| Per Week | Per Month | Per 6 Months | Per Year | |
|---|---|---|---|---|
| Rank | Login to see details | |||
| Page Views Per Million | Login to see details | |||
| Page Views Per User | Login to see details | |||
| Reach Per Million | Login to see details | |||
| Investor | Investor Type | Location | Participating Rounds |
|---|---|---|---|
| BankInvest Group | Venture Capital | Denmark | Unattributed VC - II |
| Franklin Templeton | Asset/Investment Management | San Mateo, California, United States | Unattributed VC - III |
| BayStar Capital | Venture Capital | Larkspur, California, United States | Unattributed VC - III |
| Equity4Life | Unattributed VC - III | ||
| Glyko Biomedical | Unattributed VC - II, Unattributed VC |
| Title | Application Date | Patent Date | Status (Patent / Application) |
|---|---|---|---|
| Variants of c-type natriuretic peptide | Jul 11, 2017 | Oct 20, 2020 | Patent |
| Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or condition | Feb 20, 2019 | Oct 06, 2020 | Patent |
| Tpp-1 formulations and methods for treating cln2 disease | Mar 28, 2019 | Sep 01, 2020 | Patent |
| Glucosylceramide synthase inhibitors for the treatment of diseases | Jan 18, 2019 | Sep 01, 2020 | Patent |
| Detection of oligosaccharides | Sep 15, 2017 | Jun 16, 2020 | Patent |
